That the 06-MeG temozolomide-induced adduct is the most prominent lesion is indirectly demonstrated by the evidence that glioblastomas with the reduced or absent activity of the MGMT enzyme are more sensitive to the drug. The gene discussed is MGMT; the disease is glioblastoma.